Profil Regimen Kemoterapi pada Pasien Kanker Paru Stadium III di RS X Periode 2023-2025
DOI:
https://doi.org/10.29313/bcsp.v6i2.25747Keywords:
Kanker paru, Profil pengobatan, KemoterapiAbstract
Abstract. The prescription of chemotherapy (cytostatic drugs) as the primary treatment for lung cancer must be carried out with caution and under close supervision. This study aims to determine the regimen proifle of chemotherapy to stage III lung cancer patients at X Hospital during the 2023–2025 period. The study was conducted as a descriptive observational study using a retrospective approach based on medical records of stage III lung cancer patients in the Inpatient Ward. . A total of 99 patients met the study criteria, with Non-Small Cell Lung Cancer (NSCLC) being the predominant type (92.9%). The Carboplatin–Paclitaxel regimen (45.5%) was found to be the most commonly used for NSCLC, while for Small Cell Lung Cancer (SCLC), it was the Etoposide–Carboplatin regimen (5.2%). The most commonly used supportive therapies included antiemetics, gastroprotectants, intravenous fluids and electrolytes, analgesics, corticosteroids, and bronchodilators.
Abstrak. Peresepan kemoterapi (sitostatika) sebagai modalitas utama kanker paru harus dilakukan dengan kehati-hatian dan pengawasan ketat. Penelitian ini bertujuan untuk mengetahui profil regimen kemoterapi pada pasien kanker paru stadium III di Instalasi Rawat Inap RS X periode 2023–2025. Penelitian dilakukan secara observasional deskriptif dengan pendekatan retrospektif berdasarkan data rekam medis pasien kanker paru stadium III di Instalasi Rawat Inap. Sebanyak 99 pasien memenuhi kriteria penelitian, dengan dominasi Non-Small Cell Lung Cancer (NSCLC) (92,9%). Ditemukan Regimen kemoterapi Carboplatin - Paklitaksel (45,5%) paling banyak digunakan pada NSCLC, sedangkan pada Small Cell Lung Cancer (SCLC) adalah Etoposid Carboplatin (5,2%).. Terapi suportif yang paling banyak digunakan antara lain golongan antiemetik, gastroprotektor, cairan infus dan elektorlit, analgesik, koritkosteroid, serta bronkodilator.
References
Criner, G. J., Agusti, A., Borghaei, H., Friedberg, J., Martinez, F. J., Miyamoto, C., Vogelmeier, C. F., & Celli, B. R. (2022). Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians. In Chronic Obstructive Pulmonary Diseases (Vol. 9, Number 3, pp. 454–476). COPD Foundation. Hipertensitps://doi.org/10.15326/jcopdf.2022.0296
DiPiro, J. T., Yee, G. C., Haines, S. T., Nolin, T. D., Ellingrod, V. L., & Posey, L,M. (2023). DiPiro’s Pharmacotherapy: A pathophysiologic approach (12th ed.). McGraw Hill Professional.
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018). Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 29(Suppl. 4), iv166–iv191.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2026). Global Strategy for Prevention, Diagnosis and Management of COPD 2026 Report
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., Eng, C., Feyer, P. C., Jordan, K., Noonan, K., Sparacio, D., Somerfield, M. R., & Lyman, G. H. (2020). Antiemetics: ASCO guideline update. Journal of Clinical Oncology, 38(24), 2782–2797.
Kaiyong, Z., Peiyuan, S., Huang, H. (2022). Etiology of Lung Cancer: Evidence from Epidemiologic Studies. Journal of The National Cancer Center, 2(4), 216-225
Kementerian Kesehatan Republik Indonesia. (2023). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru. Jakarta: Kementerian Kesehatan Repbulik Indonesia.
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010). Mechanisms of cisplatin nephrotoxicity. Toxins, 2(11), 2490–2518. Hipertensitps://doi.org/10.3390/toxins2112490
Nasution, V., S., Wahyuni, S., Dalimunthe, G., I., Lubis, M., S. (2025). Analisis Penggunaan Obat Kemoterapi Kanker Paru-paru di RSUD Pirngadi Koda Medan. FARMASAINKES: Jurnal Farmasi, Sains, dan Kesehatan, 4(2).
National Comprehensive Cancer Network. (2026). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines: Non Small Cell Lung Cancer (Version 3.2026). Hipertensitp://www.nccn.org.
Ofoti-Asenso, R. (2016). A Closer Look at the World Health Organization’s Prescribing Indicators. Journal of Pharmacology and Pharmacotherapeutics, 7(1), 51–54. Hipertensitps://doi.org/10.4103/0976-500X.179352
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021). Small-cell lung cancer. Nature reviews. Disease primers, 7(1), 3. Hipertensitps://doi.org/10.1038/s41572-020-00235-0.
Rusdi, N., K., Sari, E., V., Wulandari, N. (2023). Ketepatan Obatm Dosis, dan Potensi Interaksi Obat pada Pasien Kanker Paru di Rumah Sakit X Jawa Barat Periode 2019-2021. Jurnal Sains dan Kesehatan, 5 (3) Jurnal Sains dan Kesehatan (J. Sains Kes.) 2023. Vol 5. No 3. Satriani, A., Permatasari, A. N., & Firmansyah. (2022). Jurnalis Muslim Menghadapi Pandemi Covid-19 : Sebuah Antologi. CV. Simbiosa Rekatama Media.
Sawaid, I. O., & Samson, A. O. (2024). Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. Journal of clinical medicine, 13(7), 1970. Hipertensitps://doi.org/10.3390/jcm13071970
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., Coughlin, S., Kim, Y., & Berille, J. (2023). Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(15), 2673–2681. Hipertensitps://doi.org/10.1200/JCO.22.02545
Sugiyono. (2022). Metode Penelitian Kuantitaif, Kualitatif, dan R&D (4th 3e.). Bandung: Alfabeta.
Tsao, L. R., et al. (2022). Hypersensitivity reactions to platinum agents and taxanes: Epidemiology, mechanisms, and management. Clinical Reviews in Allergy & Immunology, 62(3), 432–448
Zer, A., Ahn, M. J., Barlesi, F., Bubendorf, L., De Ruysscher, D., Garrido, P., Gautschi, O.,
Hendriks, L. E., Jänne, P. A., Kerr, K. M., Mascaux, C., Mitsudomi, T., Peters, S., Rolfo, C., Sacher, A., Senan, S., Ugalde, P., Leighl, N. B., & ESMO Guidelines Committee.(2025). Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 36(11), 1245–1262. Hipertensitps://doi.org/10.1016/j.annonc.2025.08.003.
